Rie Io Glerup
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rie Io Glerup has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Jens D. Jensen
Department of Renal Medicine Aarhus University Hospital Aarhus Denmark
2 shared publicationsJeppe H. Christensen
Department of Nephrology Aalborg University Hospital Aalborg Denmark
2 shared publicationsMy Svensson
Department of Renal Medicine Akershus University Hospital Lørenskog Norway
2 shared publicationsAllan Birnum
Department of Nephrology, Aalborg University Hospital, Aalborg, Denmark
1 shared publication- Bengt Fellström
Department of Medical Sciences, Uppsala University, Uppsala, Sweden
1 shared publication Bengt Fellstrøm
Department of Medical Sciences Uppsala University Uppsala Sweden
1 shared publication
Latest Publications
- Open Access
- 20 July 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (10) , 2291-2302
Intradialytic Kinetics of Cardiac Biomarkers during High-Flux Hemodialysis and Postdilution Hemodiafiltration
Key Points: High-sensitivity cardiac troponin I, high-sensitivity cardiac troponin T, and N -terminal pro–B-type natriuretic peptide are reduced by hemodiafiltration, increasing the risk of potential misinterpretation in patients undergoing dialysis. Measuring these biomarkers during or immediately after dialysis may yield falsely low concentrations. Clinicians should consider the timing of the most recent dialysis session when interpreting cardiac biomarkers for diagnostic purposes. Background: There are limited data on how hemodialysis influences cardiac biomarker concentrations. This study aimed to investigate concentration changes of high-sensitivity troponin I and T, and N -terminal pro–B-type natriuretic peptide (NT-proBNP) before, during, and after hemodialysis and hemodiafiltration (HDF), and to compare these changes between the two dialysis modalities. Methods: Randomized crossover study including 23 stable patients treated with hemodialysis/HDF. Patients were randomized to start with high-flux hemodialysis or postdilution HDF, had a washout period of 1–3 weeks, and then crossed over to receive the other modality. Blood samples were collected before dialysis, after 10, 30, 60, 120, 180, and 240 minutes of dialysis, and 30 minutes postdialysis. In addition, spent dialysate was collected after 120 minutes of dialysis. Linear mixed-effects models were used to investigate concentration changes and compare dialysis modalities. Results: High-sensitivity troponin I and high-sensitivity troponin T were not influenced by hemodialysis; however, HDF resulted in a significant decline in both biomarkers. At the end of dialysis, the change was −7.7 ng/L (95% confidence interval [CI], −12.3 to −3.1) for high-sensitivity troponin I and −23.4 ng/L (95% CI, −31.8 to −15.0) for high-sensitivity troponin T. NT-proBNP was significantly reduced with both modalities, with a change of −2954 ng/L (95% CI, −4974 to −934) in hemodialysis and −5161 ng/L (95% CI, −7231 to −3092) in HDF. All biomarker concentrations were significantly lower with HDF compared with hemodialysis at the end of dialysis. Conclusions: High-sensitivity troponin I, high-sensitivity troponin T, and NT-proBNP were significantly reduced with HDF in asymptomatic patients treated with dialysis. Hemodialysis reduced NT-proBNP. Cardiac biomarker levels are influenced by dialysis and treatment modality, which could lead to potential misinterpretation. This emphasizes that time since the last dialysis session should be considered when interpreting cardiac biomarkers for diagnostic purposes. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT06526702.
- 20 July 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (10) , 2291-2302
Open AccessIntradialytic Kinetics of Cardiac Biomarkers during High-Flux Hemodialysis and Postdilution Hemodiafiltration
Key Points: High-sensitivity cardiac troponin I, high-sensitivity cardiac troponin T, and N -terminal pro–B-type natriuretic peptide are reduced by hemodiafiltration, increasing the risk of potential misinterpretation in patients undergoing dialysis. Measuring these biomarkers during or immediately after dialysis may yield falsely low concentrations. Clinicians should consider the timing of the most recent dialysis session when interpreting cardiac biomarkers for diagnostic purposes. Background: There are limited data on how hemodialysis influences cardiac biomarker concentrations. This study aimed to investigate concentration changes of high-sensitivity troponin I and T, and N -terminal pro–B-type natriuretic peptide (NT-proBNP) before, during, and after hemodialysis and hemodiafiltration (HDF), and to compare these changes between the two dialysis modalities. Methods: Randomized crossover study including 23 stable patients treated with hemodialysis/HDF. Patients were randomized to start with high-flux hemodialysis or postdilution HDF, had a washout period of 1–3 weeks, and then crossed over to receive the other modality. Blood samples were collected before dialysis, after 10, 30, 60, 120, 180, and 240 minutes of dialysis, and 30 minutes postdialysis. In addition, spent dialysate was collected after 120 minutes of dialysis. Linear mixed-effects models were used to investigate concentration changes and compare dialysis modalities. Results: High-sensitivity troponin I and high-sensitivity troponin T were not influenced by hemodialysis; however, HDF resulted in a significant decline in both biomarkers. At the end of dialysis, the change was −7.7 ng/L (95% confidence interval [CI], −12.3 to −3.1) for high-sensitivity troponin I and −23.4 ng/L (95% CI, −31.8 to −15.0) for high-sensitivity troponin T. NT-proBNP was significantly reduced with both modalities, with a change of −2954 ng/L (95% CI, −4974 to −934) in hemodialysis and −5161 ng/L (95% CI, −7231 to −3092) in HDF. All biomarker concentrations were significantly lower with HDF compared with hemodialysis at the end of dialysis. Conclusions: High-sensitivity troponin I, high-sensitivity troponin T, and NT-proBNP were significantly reduced with HDF in asymptomatic patients treated with dialysis. Hemodialysis reduced NT-proBNP. Cardiac biomarker levels are influenced by dialysis and treatment modality, which could lead to potential misinterpretation. This emphasizes that time since the last dialysis session should be considered when interpreting cardiac biomarkers for diagnostic purposes. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT06526702.
- Open Access
- 22 March 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (4) , 740
Novel Biomarkers Detected by Proteomics Predict Death and Cardiovascular Events in Hemodialysis Patients
End-stage kidney disease increases mortality and the risk of cardiovascular (CV) disease. It is crucial to explore novel biomarkers to predict CV disease in the complex setting of patients receiving hemodialysis (HD). This study investigated the association between 92 targeted proteins with all-cause death, CV death, and composite vascular events (CVEs) in HD patients. From December 2010 to March 2011, 331 HD patients were included and followed prospectively for 5 years. Serum was analyzed for 92 CV-related proteins using Proseek Multiplex Cardiovascular I panel, a high-sensitivity assay based on proximity extension assay (PEA) technology. The association between biomarkers and all-cause death, CV death, and CVEs was evaluated using Cox-regression analyses. Of the PEA-based proteins, we identified 20 proteins associated with risk of all-cause death, 7 proteins associated with risk of CV death, and 17 proteins associated with risk of CVEs, independent of established risk factors. Interleukin-8 (IL-8), T-cell immunoglobulin and mucin domain 1 (TIM-1), and C-C motif chemokine 20 (CCL20) were associated with increased risk of all-cause death, CV death, and CVE in multivariable-adjusted models. Stem cell factor (SCF) and Galanin peptides (GAL) were associated with both decreased risk of all-cause death and CV death. In conclusion, IL-8, TIM-1, and CCL20 predicted death and CV outcomes in HD patients. Novel findings were that SCF and GAL were associated with a lower risk of all-cause death and CV death. The SCF warrants further study with regard to its possible biological effect in HD patients.
- 22 March 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (4) , 740
Open AccessNovel Biomarkers Detected by Proteomics Predict Death and Cardiovascular Events in Hemodialysis Patients
End-stage kidney disease increases mortality and the risk of cardiovascular (CV) disease. It is crucial to explore novel biomarkers to predict CV disease in the complex setting of patients receiving hemodialysis (HD). This study investigated the association between 92 targeted proteins with all-cause death, CV death, and composite vascular events (CVEs) in HD patients. From December 2010 to March 2011, 331 HD patients were included and followed prospectively for 5 years. Serum was analyzed for 92 CV-related proteins using Proseek Multiplex Cardiovascular I panel, a high-sensitivity assay based on proximity extension assay (PEA) technology. The association between biomarkers and all-cause death, CV death, and CVEs was evaluated using Cox-regression analyses. Of the PEA-based proteins, we identified 20 proteins associated with risk of all-cause death, 7 proteins associated with risk of CV death, and 17 proteins associated with risk of CVEs, independent of established risk factors. Interleukin-8 (IL-8), T-cell immunoglobulin and mucin domain 1 (TIM-1), and C-C motif chemokine 20 (CCL20) were associated with increased risk of all-cause death, CV death, and CVE in multivariable-adjusted models. Stem cell factor (SCF) and Galanin peptides (GAL) were associated with both decreased risk of all-cause death and CV death. In conclusion, IL-8, TIM-1, and CCL20 predicted death and CV outcomes in HD patients. Novel findings were that SCF and GAL were associated with a lower risk of all-cause death and CV death. The SCF warrants further study with regard to its possible biological effect in HD patients.
- 29 December 2021
- Published by Wiley in Hemodialysis International
- Vol. 26 (2) , 191-201
Multiplex proteomics as risk predictor of infection in patients treated with hemodialysis—A prospective multicenter study
Introduction: Severe infection is a major problem in hemodialysis patients. Multiplex proteomics might reveal novel insights into disease mechanisms increasing the risk of infection and might also be used as a risk prediction tool. The aims of this study were (1) to evaluate associations between 92 proteins assessed by a proximity extension assay and the development of severe infection in patients on hemodialysis and (2) to develop a risk prediction model for severe infection using prespecified clinical variables and proteomics.Methods: Prospective, observational multicenter cohort study with 5‐year follow‐up. Patients receiving in‐center hemodialysis in five facilities in Denmark were included. The primary composite endpoint was death caused by infection, bacteremia, and infections requiring hospitalization of at least 2 days or prolonging a hospital stay.Findings: Of 331 patients included 210 patients reached the primary endpoint during follow‐up. In adjusted Cox regression analyses, 14 plasma proteins were associated with severe infection. Correcting for multiple testing revealed only cathepsin‐L1 and interleukin‐6 significantly associated with the primary outcome. Cathepsin‐L1—hazard ratio: 1.64 (95% confidence interval [CI] 1.24–2.17) and interleukin‐6—hazard ratio: 1.16 (95% CI 1.05–1.29). Apparent C‐statistics of the risk prediction model using clinical variables was 0.605, addition of cathepsin‐L1 and interleukin‐6 to the model improved discrimination slightly: C = 0.625.Discussion: Proteomic profiling identified cathepsin‐L1 and interleukin‐6 as markers for infectious risk in hemodialysis patients. Further studies are needed to replicate the results and to examine possible causality. The developed risk prediction models need considerable improvement before implementation in clinical practice is meaningful.
- 29 December 2021
- Published by Wiley in Hemodialysis International
- Vol. 26 (2) , 191-201
Multiplex proteomics as risk predictor of infection in patients treated with hemodialysis—A prospective multicenter study
Introduction: Severe infection is a major problem in hemodialysis patients. Multiplex proteomics might reveal novel insights into disease mechanisms increasing the risk of infection and might also be used as a risk prediction tool. The aims of this study were (1) to evaluate associations between 92 proteins assessed by a proximity extension assay and the development of severe infection in patients on hemodialysis and (2) to develop a risk prediction model for severe infection using prespecified clinical variables and proteomics.Methods: Prospective, observational multicenter cohort study with 5‐year follow‐up. Patients receiving in‐center hemodialysis in five facilities in Denmark were included. The primary composite endpoint was death caused by infection, bacteremia, and infections requiring hospitalization of at least 2 days or prolonging a hospital stay.Findings: Of 331 patients included 210 patients reached the primary endpoint during follow‐up. In adjusted Cox regression analyses, 14 plasma proteins were associated with severe infection. Correcting for multiple testing revealed only cathepsin‐L1 and interleukin‐6 significantly associated with the primary outcome. Cathepsin‐L1—hazard ratio: 1.64 (95% confidence interval [CI] 1.24–2.17) and interleukin‐6—hazard ratio: 1.16 (95% CI 1.05–1.29). Apparent C‐statistics of the risk prediction model using clinical variables was 0.605, addition of cathepsin‐L1 and interleukin‐6 to the model improved discrimination slightly: C = 0.625.Discussion: Proteomic profiling identified cathepsin‐L1 and interleukin‐6 as markers for infectious risk in hemodialysis patients. Further studies are needed to replicate the results and to examine possible causality. The developed risk prediction models need considerable improvement before implementation in clinical practice is meaningful.
- Open Access
- 1 September 2019
- Published by Elsevier in Kidney Medicine
- Vol. 1 (5) , 263-270
Staphylococcus aureus Bacteremia Risk in Hemodialysis Patients Using the Buttonhole Cannulation Technique: A Prospective Multicenter Study
- 1 September 2019
- Published by Elsevier in Kidney Medicine
- Vol. 1 (5) , 263-270
Open AccessStaphylococcus aureus Bacteremia Risk in Hemodialysis Patients Using the Buttonhole Cannulation Technique: A Prospective Multicenter Study